If you were a registrant for the 2021 Annual Convention, please click here to complete your evaluations and claim Nursing Continuing Professional Development (NCPD) contact hours. The evaluation deadline for convention registrants is April 3, 2022.
The session discusses pharmacologic agents used to treat type 1 and type 2 diabetes. 2021 is the 100-year anniversary of insulin and this session describes how insulin has evolved over time. Case studies are reviewed.
Continuing Education Instructions and Disclosure Information:
Contact hours available until 10/3/23.
Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online nursing continuing professional development (NCPD) evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.
Faculty, Planners, and Speakers Conflict of Interest Disclosure:
Planning Committee Disclosures: There are no disclosures to declare.
Speakers Conflict of Interest Disclosure: Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES discloses that she serves on the speakers' bureau for Novo Nordisk, Insulet, Medtronic, Abbott, Dexcom, and Xeris Pharmaceuticals.
There are no other speaker disclosures to declare.
Commercial Support and Sponsorship: No commercial support or corporate sponsorship was received.
Accreditation Statement: This session is jointly provided by Anthony J. Jannetti, Inc. (AJJ) and the Academy of Medical-Surgical Nurses (AMSN).
Anthony J Jannetti, Inc. is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Anthony J. Jannetti, Inc. is an approved provider of continuing nursing education by the California Board of Registered Nurses, Provider Number CEP 5387.
Learning Outcome: After completing this learning activity, the participant will develop evidence-based and individualized medication plans for various types of people with diabetes.